2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5887 Sequential B-cell aplasia and repertoire reset revealed by longitudinal single-cell profiling after allogeneic CD19/BCMA CAR-T therapy in refractory SLE-ITP

zhixiang yan, Ying Wang, MD, PhD2, Yanan Yue3, yiwen zhou4, xiaobin song5, lihong shen6, pengying zhang7, tianying chen8, Yingyong Xu, MD, PhD, MBA9, Jianxiang Wang Sr, MD, PhD10, Mengtao Li11, Luhan Yang, PhD12
1 Qihan Biotechnology, Hangzhou, China
2 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
3 Qihan Biotechnology, Hangzhou, China
4 Qihan Biotechnology, Hangzhou, China
5 Qihan Biotechnology, Hangzhou, China
6 Qihan Biotechnology, Hangzhou, China
7 Qihan Biotechnology, Hangzhou, China
8 Qihan Biotechnology, Hangzhou, China
9 Qihan Biotechnology, Hangzhou, China
10 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
11 Peking Union Medical College Hospital, beijing, China
12 Qihan Biotechnology, Hangzhou, China

Background:
Systemic lupus erythematosus–associated immune thrombocytopenia (SLE-ITP) is sustained by autoreactive B cells, plasmablasts, and long-lived antibody-secreting cells. Incomplete elimination of pathogenic B-lineage compartments may permit persistent or recurrent autoreactivity. QT-019B is an off-the-shelf allogeneic CD19/BCMA dual-target CAR-T product designed to induce broad B-lineage depletion and immune reset. We performed longitudinal single-cell and B-cell receptor profiling to define the sequence from early B-cell clearance to immune reconstitution.

Methods:

Seven patients with refractory SLE-ITP received a single infusion of QT-019B. Thirty-one longitudinal samples were analyzed, including 19 peripheral blood mononuclear cell and 12 bone marrow samples collected at baseline, Days 3–8, and Months 3 and 6. Two patients underwent intensive peripheral blood sampling during the first week. Single-cell RNA sequencing and paired BCR sequencing were used to assess immune-cell composition, B-cell differentiation states, immunoglobulin isotypes, somatic hypermutation, IGHV usage, IGHV4-34 frequency, and longitudinal BCR clonotype overlap.

Results:

Rapid and profound B-lineage depletion:In both patients with intensive early sampling, B cells became undetectable by single-cell RNA sequencing at Days 3–4 and remained absent at Days 7–8. Plasmablast/plasma-cell populations were also absent or markedly depleted, providing direct evidence of rapid B-lineage aplasia. Reconstitution with immature B-cell populations:B cells re-emerged at Months 3 and 6 and were enriched for immature, transitional, and naïve states, whereas pretreatment memory, activated, plasmablast, and antibody-secreting populations remained substantially reduced. Similar patterns in peripheral blood and bone marrow supported systemic B-cell reconstitution. Recovery of a less antigen-experienced repertoire:Reconstituted B cells showed increased unswitched IgM/IgD usage, reduced class-switched immunoglobulins, lower somatic hypermutation, and decreased IGHV4-34 frequency. These findings indicated recovery dominated by newly generated, less antigen-experienced B cells, accompanied by contraction of autoreactivity-associated repertoire features. Marked BCR clonal remodeling:No shared BCR clonotypes were detected between baseline and post-treatment samples in the analyzed peripheral blood or bone marrow datasets. In contrast, limited overlap was observed between Months 3 and 6, with six shared clonotypes in peripheral blood and four in bone marrow, confirming that persistent post-treatment clones were detectable. Although finite sampling could not exclude all residual baseline clones, these findings supported marked disruption of the pretreatment repertoire. Consistent remodeling across patients and compartments:Despite interpatient differences in baseline immune composition and sample availability, all seven patients showed a consistent trajectory of profound B-cell depletion followed by reconstitution of a phenotypically and molecularly less experienced B-cell compartment.

Conclusions:
QT-019B induced a sequential two-stage response in refractory SLE-ITP: rapid, profound B-cell aplasia followed by repopulation with immature, predominantly unswitched B cells showing lower somatic hypermutation and reduced IGHV4-34 usage. The limited continuity between baseline and post-treatment BCR repertoires provides sampling-dependent evidence of substantial clonal remodeling. These findings indicate that allogeneic CD19/BCMA CAR-T therapy induces not only transient B-cell depletion but coordinated cellular and molecular resetting of the B-cell immune compartment.

Luhan Yang, PhD: No relevant conflicts of interest to declare.